FDA NAMs-Aligned
Predictive Toxicology
AI-Driven Analytics
Human-Centric Models
Digital Organ Twins
Quantum-Enhanced Modeling
Patented Technology
Precision Disease Models
Reduced Animal Testing
FDA NAMs-Aligned
Predictive Toxicology
AI-Driven Analytics
Human-Centric Models
Digital Organ Twins
Quantum-Enhanced Modeling
Patented Technology
Precision Disease Models
Reduced Animal Testing
Dr. Velpandi Ayyavoo is a molecular virologist with over three decades of expertise in 3D brain oranoids, HIV-1 virology, host–pathogen interactions, and translational research. Her laboratory investigates the mechanisms by which HIV-1 drives pathogenesis, with particular emphasis on its impact on both the peripheral and central nervous systems (CNS) of people with HIV (PWH). By integrating autopsied brain tissue with physiologically relevant 3D brain organoid models, her group has uncovered significant neuronal alterations linked to HIV-associated cognitive impairment and neurodegenerative conditions.
She has authored more than 80 peer-reviewed publications, delivered numerous invited lectures, and holds several international patents. CNS diseases, including those caused by pathogens and neurodegenerative conditions, exhibit a wide range of clinical outcomes from asymptomatic states to severe cognitive decline. Investigating their underlying mechanisms is particularly challenging due to the intricate interactions between neural and glial networks.